
The Infectious Diseases Society of America issued guidance to help clinicians manage drug interactions between Paxlovid and the 100 most prescribed medications.
Additionally, the FDA said there is no evidence to suggest that a longer course of Paxlovid will benefit patients who experience a rebound in COVID-19 symptoms after completing a 5-day course of the medication.
Pfizer received an emergency use authorization for Paxlovid — which consists of the protease inhibitor nirmatrelvir and a low dose of ritonavir — in late December, making it the first available oral antiviral for